UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Decreases Holdings in Zoetis Inc. $ZTS

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC decreased its holdings in Zoetis Inc. (NYSE:ZTS) by 10.8% in the second quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 3,924,988 shares of the company’s stock after selling 473,363 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC owned approximately 0.95% of Zoetis worth $282,050,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently made changes to their positions in the business. Prosperity Bancshares Inc purchased a new stake in Zoetis during the fourth quarter valued at about $25,000. Cassaday & Co Wealth Management LLC purchased a new position in shares of Zoetis in the first quarter worth about $28,000. Elyxium Wealth LLC bought a new stake in shares of Zoetis in the 4th quarter valued at about $32,000. Root Financial Partners LLC lifted its stake in shares of Zoetis by 66.5% in the 1st quarter. Root Financial Partners LLC now owns 258 shares of the company’s stock valued at $30,000 after acquiring an additional 103 shares during the last quarter. Finally, Wellington Grp LLC boosted its holdings in Zoetis by 6,675.0% during the 1st quarter. Wellington Grp LLC now owns 271 shares of the company’s stock valued at $32,000 after acquiring an additional 267 shares during the period. Institutional investors own 92.80% of the company’s stock.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ZTS shares. Citigroup reduced their price target on Zoetis from $112.00 to $96.00 and set a “buy” rating on the stock in a research report on Tuesday, August 11th. William Blair reissued a “market perform” rating on shares of Zoetis in a research note on Thursday, August 6th. Stifel Nicolaus dropped their price objective on Zoetis from $85.00 to $80.00 and set a “hold” rating for the company in a research note on Thursday, August 20th. UBS Group cut their target price on shares of Zoetis from $85.00 to $80.00 and set a “neutral” rating on the stock in a report on Friday, August 7th. Finally, HSBC decreased their target price on shares of Zoetis from $140.00 to $95.00 and set a “buy” rating on the stock in a research note on Monday, July 6th. Eight investment analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and two have issued a Sell rating to the stock. According to MarketBeat.com, Zoetis currently has a consensus rating of “Hold” and an average price target of $107.43.

Zoetis Stock Down 0.5%

Shares of NYSE:ZTS opened at $76.99 on Tuesday. Zoetis Inc. has a 1 year low of $71.00 and a 1 year high of $156.49. The company has a market cap of $31.81 billion, a PE ratio of 12.68, a P/E/G ratio of 1.80 and a beta of 0.73. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock’s 50-day moving average is $75.59 and its 200 day moving average is $95.04.

Zoetis (NYSE:ZTS) last released its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share for the quarter, topping the consensus estimate of $1.85 by $0.02. The business had revenue of $2.47 billion during the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The business’s revenue was down .2% on a year-over-year basis. During the same quarter last year, the business posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Sell-side analysts anticipate that Zoetis Inc. will post 6.2 EPS for the current year.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.